PGHLProcter & Gamble Health Ltd.

₹6107-1.48%

Market Cap

₹0.00 Cr

Stock P/E

0.00

ROCE

0.00%

ROE

0.00%

Book Value

₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Strong 9-month FY performance with solid revenue and profit growth.
•
Five-year growth trajectory shows durable top-line and margin expansion under the Integrated Growth Strategy.

NEGATIVES

•
Vitamin Mineral & Supplement category shows pricing-led growth with flat volume.
•
Competition from generic Vitamin-B products may limit efficacy and sustain substitution risks.

Peers Summary

Sector Leader

Procter & Gamble Health Ltd. shows no growth metrics and lacks profitability, placing it at a disadvantage compared to its peers. Companies like Cipla and Dr. Reddy's are standout performers with strong profitability and valuation metrics, while others like Sun Pharma are struggling with high valuations despite decent growth.

Key Points

• Procter & Gamble Health Ltd. lacks growth and profitability metrics, with a PE ratio of 41.72 but no revenue or EPS growth.
• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit strong profitability with ROE over 16% and PE ratios that suggest they are undervalued relative to growth prospects.
• Sun Pharmaceutical Industries Ltd. shows high growth but at a steep valuation, indicating it may be overvalued at a PE of 87.59.

Top Performers

Cipla Ltd.

Strong revenue growth (YoY: 13.28%) and low PE (23.73) makes it an attractive investment.

Dr. Reddy's Laboratories Ltd.

Excellent profitability metrics with a PE of 15.50 and high ROE of 21.76%.

Mankind Pharma Ltd.

Impressive revenue growth (YoY: 18.12%) and reasonable PE of 55.18, indicating strong market position.

Explore

Watchlists